Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q4.

Zacks Equity Research

Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN

by Zacks Equity Research

Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.

Zacks Equity Research

NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater

by Zacks Equity Research

Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.

Zacks Equity Research

Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag

by Zacks Equity Research

Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y

by Zacks Equity Research

The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.

Zacks Equity Research

Is Hologic (HOLX) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows

by Zacks Equity Research

TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.

Zacks Equity Research

Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.

by Zacks Equity Research

Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.

Zacks Equity Research

DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

DaVita's (DVA) bottomline in Q4 declines year over year.

Zacks Equity Research

HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HOLX vs. SMLR: Which Stock Is the Better Value Option?

Zacks Equity Research

DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

Zacks Equity Research

Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis

by Zacks Equity Research

In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Zacks Equity Research

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

by Zacks Equity Research

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Zacks Equity Research

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Zacks Equity Research

Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

Zacks Equity Research

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

Zacks Equity Research

Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry

by Zacks Equity Research

Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.

Zacks Equity Research

Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.

Zacks Equity Research

Top Ranked Growth Stocks to Buy for February 11th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 11th

Kevin Cook headshot

Bull of the Day: Meridian Bioscience (VIVO)

by Kevin Cook

Small-cap diagnostics player will grow sales 30%+ to over $335 million on COVID-19 testing and its mutations